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Abstract
Background: Approximately 80,000 patients each year are admitted to UK hospitals with an acute stroke and are
immobile. At least 10% will develop a proximal Deep Vein Thrombosis in the first month and 1.5% a pulmonary
embolus. Although hydration, antiplatelet treatment and early mobilisation may reduce the risk of deep vein
thrombosis, there are currently no preventive strategies which have been clearly shown to be both effective and
safe. Anticoagulation increases the risks of bleeding and compression stockings are ineffective. Systematic reviews
of small randomized trials of intermittent pneumatic compression have shown that this reduces the risk of deep
vein thrombosis in patients undergoing surgery, but that there are few data concerning its use after stroke. The
CLOTS trial 3 aims to determine whether, compared with best medical care, best medical care plus intermittent
pneumatic compression in immobile stroke patients reduces the risk of proximal deep vein thrombosis.
Methods/Design: CLOTS Trial 3 is a parallel group multicentre trial; with centralized randomisation (minimisation)
to ensure allocation concealment. Over 80 centres in the UK will recruit 2800 immobile stroke patients within the
first 3 days of their hospital admission. Patients will be allocated to best medical care or best medical care plus
intermittent pneumatic compression. Ultrasonographers will perform a Compression Duplex Ultrasound Scan to
detect deep vein thrombosis in each treatment group at about 7-10 days and 25-30 days. The primary outcome
cluster includes symptomatic or asymptomatic deep vein thrombosis in the popliteal or femoral veins detected on
either scan. Patients are then followed up by postal or telephone questionnaire at 6 months from randomisation to
detect later symptomatic deep vein thrombosis and pulmonary emboli and to establish their functional outcome
(Oxford handicap scale) and quality of life (EQ5D-3 L). The ultrasonographers performing the scans are blinded to
treatment allocation, whereas the patients and caregivers are not. The trial has 90% power to detect a 4% absolute
difference in risk of the primary outcome and includes a health economic analysis.
Discussion: The trial started recruitment in Dec 2008 and will complete recruitment during 2012. It will report
results in 2013.
Trial registration number: ISRCTN: ISRCTN93529999
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A House of Commons Health Committee highlighted in
2005 the very large number of patients dying in UK hos-
pitals from venous thromboembolism and called for
more effective prophylaxis [1]. Studies reported over the
last 30 years have shown that deep vein thrombosis
(DVT) is particularly common in patients with a recent
stroke. Patients with significant weakness of the leg and
who are immobile appear to be at greatest risk. Studies
with magnetic resonance imaging demonstrated DVT in
40% of stroke patients within the first three weeks, and
above knee DVT in 18% [2]. Studies using less sensitive
screening techniques, such as compression duplex ultra-
sound (CDU), demonstrateal o w e rf r e q u e n c yo fa b o v e
knee DVT of about 10% although the types of patients
included and the duration and timing of follow up influ-
ences the estimates [3]. Clinically apparent DVT con-
firmed on investigation is less common but DVTs may
not be recognised and may still cause important compli-
cations. Pulmonary embolism (PE) is an important cause
of preventable death after stroke [4]. Clinically evident
PE has been variably estimated to affect one to 16% of
patients in prospective trials [5] and three to 30% in
observational studies [6]. In the CLOTS Trial 1 about
5% of patients developed symptomatic DVT and 1.5%
h a dac o n f i r m e dP Ei nt h ef i r s tm o n t ha f t e rs t r o k e[ 3 ] .
The rate of PE is likely to be underestimated because
they are not routinely screened for, and autopsies are
rarely performed. Many patients who have pneumonia
or unexplained fever may actually have pulmonary
emboli. Fifty percent of patients who die following an
acute stroke showed evidence of PE on autopsy [7]. Stu-
dies, like the CLOTS Trial 1, which screen for DVT
may under-estimate the clinical importance of venous
thromboembolism because patients are usually treated
whilst still asymptomatic so their risk of developing
symptomatic DVT and pulmonary embolism is reduced.
Traditionally a number of interventions have been
used to reduce the risk of DVT. These include:
Anticoagulants: A Cochrane review showed that both
low and medium dose subcutaneous heparin reduce the
risk of DVT, and probably PE, in patients with acute
ischaemic stroke [5]. However, evidence from the Interna-
tional Stroke Trial [8] showed that even low dose heparin
(5,000 units twice daily) is associated with a significant
excess of symptomatic intracranial and extracranial bleeds
which offsets any other advantages heparin may have on
recurrent ischaemic stroke and fatal PE. The PREVAIL
Trial compared the effectiveness, and safety of standard
prophylactic heparin with low molecular weight heparin
(LMWH) [9]. It demonstrated that LMWH was probably
more effective than standard heparin in reducing the risk
of mainly asymptomatic DVTs but it was not powered to
identify clinically significant differences in risk. More
importantly it does not, despite reports to the contrary,
provide any evidence that routine heparin or LMWH use
is associated with net benefit - it had no “avoid any
heparin” control group [10].
Graduated Compression Stockings (GCS): Although,
GCS seem to reduce the risk of DVT in patients under-
going surgery [11,12], the CLOTS Trial 1 showed that
thigh-length GCS were not associated with a clinically
useful reduction in the risk of post stroke DVT (abso-
lute reduction in risk of proximal DVT = 0.5% (95%CI
-1.9 to 2.9))[3,13].
Intermittent Pneumatic Compression (IPC): This com-
prises a pair of inflatable sleeves which are wrapped
around the legs and are secured by Velcro™.T h e ya r e
attached via flexible tubing to a small bedside electric
pump. The sleeves may be short (or below knee), wrap-
ping around just the lower leg, or long (thigh length) to
wrap around the thigh as well. They are inflated one
s i d ea tat i m et oc o m p r e s st h el e g sa ti n t e r v a l s .S o m e
types inflate sequentially, first around the lower leg and
then the upper, to “milk” the blood from the leg and
increase venous flow. The frequency of inflation can be
fixed, or in more sophisticated systems varies depending
upon the rate of venous refill. IPC is thought to reduce
the risk of venous thrombosis by:
￿ increasing the flow of venous blood through the
deep veins of the leg to reduce the likelihood of
thrombosis.
￿ stimulating release of intrinsic fibrinolytic
substances.
IPC has mainly been used in surgical patients during
and immediately after operations. A systematic review
identified 22 randomised trials of IPC, which included a
total of 2779 patients. Use of IPC was associated with a
6 4 %r e d u c t i o ni nt h eo d d so fD V T( p < 0.00001) [12].
This review concluded that a priority for future research
w a st r i a l so f“prevention of venous thromboembolism
with mechanical methods among high-risk medical
patients (such as those with stroke)”.
A Cochrane review [13] of the effectiveness of physical
means of reducing the risk of venous thromboembolism
after stroke identified only two small trials of IPC
including just 177 patients in total. IPC was associated
with a non-significant trend towards a lower risk of
DVTs (OR 0.45, 95% CI 0.19 to 1.10) with no evidence
of an effect on deaths (OR 1.04, 95% CI 0.37 to 2.89).
Thus, the available evidence confirms that after stroke,
even applying current prophylactic strategies, the risk of
venous thromboembolism is substantial. The available
data suggest that IPC is a promising, but unproven and
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1. Establish whether the routine application of IPC
to the legs of immobile stroke patients reduces their
risk of DVT and PE.
2. Determine whether IPC adds to the benefits of
r o u t i n ec a r ew h i c ho f t e ni n c l u d e sg o o dh y d r a t i o n ,
early use of aspirin and mobilisation.
3. Quantify any risks of IPC when applied to stroke
patients.
4. Estimate the cost-effectiveness of IPC which will
help health service planners decide whether IPC
should be offered routinely in the UK NHS.
5. Provide robust estimates of the effectiveness of
IPC in stroke patients which might be extrapolated
to other groups of medical (rather than surgical)
patients at high risk of venous thromboembolism.
Methods/Design
Design overview
CLOTS trial 3 is a multicentre, parallel group trial with
a centralized randomisation system to allocate treatment
with a 1:1 ratio, and which ensures allocation conceal-
ment (see Figure 1). Its methods are very similar to
those of CLOTS trial 1 & 2 [3,14]. We aim to blind the
ultrasonographers, who carry out the scans to detect
DVTs, but are unable to blind the patients and their
caregivers to allocation group because of the nature of
the intervention. The Multicentre Research Ethics Com-
mittees in the UK and the local ethics committees in all
contributing centres approve our protocol. We obtain
written informed consent from all patients, or for
patients lacking mental capacity, from the patients’ per-
sonal legal representatives. The trial is registered
(ISRCTN93529999).
Setting and participants
Our collaborators in more than 80 centres in the UK
aim to enrol at least 2800 patients. To participate, hos-
pitals have to have: a local principal investigator who
takes responsibility for the trial governance; a well orga-
nised inpatient stroke service; nursing staff trained in
the use of IPC; and a diagnostic ultrasound department
which routinely performs CDU.
Inclusion criteria
￿ Any patient admitted to hospital within 3 days of a
clinical stroke fulfilling the WHO criteria.
and
￿ W h oi sn o ta b l et og e tu pf r o mac h a i r / o u to fb e d
and walk to the toilet without the help of another
person
Patients can be randomised from Day 0 (day of admis-
sion) to Day 3 of hospital admission. If a patient has a
stroke during a hospital admission they are eligible until
D a y3f r o mt h es t r o k eo n s e t( D a y0 ) .S t r o k es h o u l db e
the most likely clinical diagnosis but a visible infarction
does not have to be seen on a brain scan.
Exclusion criteria
￿ Patients under 16 year of age
￿ Patients with stroke due to subarachnoid
haemorrhage.
￿ Patients who, in the opinion of the responsible
clinician/nurse, are unlikely to benefit from IPC - for
instance, this would include patients who are
expected to mobilise within the next day.
￿ Patients with contraindications for the use of IPC.
These include:
○ patients with local leg conditions in which the
IPC sleeves would interfere such as dermatitis,
○ patients with severe arteriosclerosis or as indi-
cated by absence of pedal pulses or history of
definite intermittent claudication.
○ patients who have massive leg oedema or pul-
monary oedema from congestive heart failure.
￿ Patients who already have swelling or other signs
of an existing DVT. Such patients may be recruited
once a DVT has been excluded by normal D Dimers
or CDU. There is a concern that if one applied IPC
to patients who may already have a DVT it may dis-
place the thrombus and increase the risk of PE.
However, this potential risk has not been documen-
ted in the RCTs so far. And we have not identified
any case reports where there is convincing evidence
that this has occurred.
Inclusion in another research study, including another
randomised controlled trial, does not automatically
exclude a patient from participating in CLOTS 3. As
long as inclusion in the other study would not confound
the results of CLOTS 3, co-enrolment is permissible.
Also, local researchers must avoid overburdening
patients. Patients should not be co-enrolled in another
research study which aims to test an intervention which
aims to reduce the risk of venous thromboembolism.
Consent
The patient, or their legal representative, are approached
by a member of the clinical team looking after that
patient to ascertain their interest in participating in the
CLOTS 3 trial or to obtain their permission to pass
their details onto any research staff involved. Written
informed consent is sought where possible. If this is not
possible the randomising clinician or nurse can gain wit-
nessed verbal consent. Patients or legal representatives
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any questions they may have about the implications of
the trial.
Randomisation and interventions
Having obtained consent, the clinician enters the
patient’s baseline data into our computerised central
randomisation service via a secure web interface or a
touch-tone telephone system. We encourage clinicians
to enrol patients as early as possible since prophylaxis
for DVT will have greater effect if started early. Once
the computer program has checked these baseline data
for completeness and consistency, it generates that
patient’s treatment allocation - either “best medical care
plus IPC” or “best medical care alone”. The system
applies a minimisation program to achieve balance for
four prognostic factors:
￿ Delay since stroke onset. (Day 0 or 1 vs. Day 2-7)
￿ Stroke severity (using a validated prognostic model
[15] which includes the following factors; age, pre
stroke dependency in activities of daily living, living
with another person prior to stroke, able to talk and
orientated in time, place and person, and able to lift
both arms to horizontal position against gravity).
￿ Severity of leg paresis (able or not to lift leg off the
bed)
￿ Use of heparin, warfarin or thrombolysis at the
time of enrolment
Because simple minimisation can theoretically lead to
alternation of treatment allocation, our system also
Receive information
about the CLOTS 3 study
If willing to join
sign consent form
Randomly allocated
to either
Normal care +
Intermittent 
Pneumatic
Compression
Normal care
including:
Aspirin if indicated
at  7-10 days
1st Ultrasound
at 25-30 days 
2nd Ultrasound
at 6 months
Postal questionnaire or
Telephone follow up
Ultrasound of leg veins
to look for DVT
at 7-10 days
1st Ultrasound
at 25-30 days 
2nd Ultrasound
at 6 months
Postal questionnaire or
Telephone follow up
The CLOTS 3 
study
at a glance
Figure 1 Simplified trial flowchart.
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cates patients to the treatment group that minimises the
difference between the groups with a probability of 0.8
rather than 1.0[16]. This helps to guarantee allocation
concealment.
If allocated IPC, nursing staff size, fit and apply the
sleeves, based on the manufacturers (Covidien,MA,
USA) instructions, to both legs as soon as possible after
the randomisation phone call. The IPC sleeves should
be worn both day and night, whilst the patient is in the
bed or chair for 30 days from randomisation OR until a
second screening CDU has been performed (if after 30
days), OR it may be removed earlier if the:
￿ patient is independently mobile around the ward (i.
e. can get up from a chair/out of bed and walk to
the toilet without the help of another person).
￿ patient is discharged from the participating hospi-
tal. If the patient is transferred to a rehabilitation
unit where it is practical to continue the IPC and
monitor its use appropriately then IPC should be
continued until independently mobile or the patient
declines to continue or an adverse effect of IPC
occurs. If IPC cannot be continued after transfer to
a rehabilitation unit a discharge form should be
completed at the time of transfer to the rehabilita-
tion unit.
￿ patient declines to continue to have IPC applied.
￿ healthcare staff identify any adverse effect of the
IPC (such as pressure ulcers, falls due to the IPC)
which they judge make continued application of the
IPC unwise.
If the IPC is removed for any other reason e.g. check-
ing the legs, bathing, screening CDU, then the IPC
should be replaced as soon as possible. If the sleeves
become soiled they should be replaced with new sleeves
as soon as possible.
Our recruitment coordinator and representatives of
Covidien provide onsite training to nursing staff in the
correct sizing, fitting and monitoring of IPC. This is
supplemented by a training video and web-based train-
i n g .W ea s kn u r s i n gs t a f ft or e c o r dt h e i ru s eo fI P Co n
the medication chart to increase compliance and aid
monitoring. We stipulate that both treatment groups
should receive the same medical care that could include,
depending on local protocols, early mobilisation, hydra-
tion, antiplatelet or anticoagulant drugs. The local coor-
dinator extracts information from the medication charts
on the compliance with IPC and use of antiplatelet and
anticoagulant drugs during the admission and records
this on our hospital discharge form, so we can check
that these aspects of medical care are used equally in
the treatment groups.
Outcomes and follow-up
Primary outcome
The primary outcome is the occurrence of either: a
symptomatic or asymptomatic DVT in the popliteal or
femoral veins (detected on the first or second CDU per-
formed as part of the trial protocol) or a symptomatic
DVT in the popliteal or femoral veins, confirmed on
imaging (either CDU or venography) within 30 days of
randomisation. We focus on proximal DVTs because
they are much more reliably detected by ultrasound and
are generally regarded as clinically more important
[17,18].
Secondary outcomes
In hospital or within 30 days:
￿ Death within 30 days
￿ Presence of definite or probable DVT in the popli-
teal or femoral veins detected on a screening CDU
scan which had not been suspected clinically before
the scan (see below)
￿ Definite (i.e. excluding probable DVTs) sympto-
matic or asymptomatic DVT in the popliteal or
femoral veins detected on either a CDU scan or con-
trast venography or MRI direct thrombus imaging
within 30 days of randomisation;,
￿ Any definite or probable symptomatic or asympto-
matic DVT (i.e. including DVTs which only involve
the calf veins),
￿ Confirmed fatal or non-fatal PE,
￿ Adherence to allocated treatment
￿ Adverse events related to IPC within 30 days of
randomisation.
￿ At six months:
￿ death from any cause
￿ any confirmed symptomatic or asymptomatic DVT
or PE occurring between randomisation and final
follow up
￿ any symptomatic DVT or PE occurring between
randomisation and final follow up
￿ place of residence,
￿ post DVT syndrome,
￿ functional status, three simple questions [19] and
Oxford handicap scale [20],
￿ health related quality of life (EuroQol)[21].
Adverse events
Stroke is a serious medical condition. About 20% of hos-
pitalized patients would be expected to die. Serious medi-
cal complications are common. CLOTS 3 is evaluating
IPC, a non-drug intervention which has a CE mark and
has been approved for the purpose of reducing the risks
of venous thromboembolism. The risks associated with
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erally predictable e.g. skins problems on legs, falls result-
ing in injury. It should be relatively straightforward to
attribute any serious adverse event to the IPC. In this
trial we therefore do not require routine reporting of any
adverse events since this is unlikely to be informative and
places an unnecessary burden on the local researchers
which would compromise the practicality of the trial. We
do require prompt reporting of primary and secondary
outcomes on the radiology report form (within 2 working
days), discharge form (within 10 working days), General
Practitioner questionnaire and hospital follow up forms.
The following should be reported on the radiology
report form, discharge form or General Practitioner
questionnaire (if patient has been discharged) or hospital
6 month follow up form (if the patient is still in hospital):
￿ Any confirmed DVT
￿ Any confirmed pulmonary embolus
￿ Any fall associated with significant injury occurring
within 30 days of enrollment (when IPC might still
be applied) - an injury requiring investigation, or
specific treatment or which prolongs hospitalisation
or leads to death, temporary or permanent disability.
￿ A n yd a m a g et ot h es k i no ft h el e g si n c l u d i n g
necrosis, ulcers occurring within 30 days of
enrollment
￿ Reasons for prematurely stopping the IPC
The following are expected complications of stroke
and its co-morbidities and do not need to be reported
as Adverse Events:
￿ Deaths - these should be reported as outcome
events on the discharge or 6 month follow up forms
￿ Infections other than those affecting the skin of the
legs
￿ Further vascular events (including recurrent
strokes, myocardial infarction, bowel ischaemia)
￿ Cardiac, renal or liver problems
￿ Epileptic seizures
￿ Spasticity or contractures
￿ Painful shoulder and other joint problems
￿ Mood disturbances
Any other adverse events which the investigator feels
may be due to either the treatment or participation in
the trial should be reported within 10 working days to
the coordinating centre. A serious adverse event (i.e.
one resulting in death, is life threatening, results in sig-
nificant disability or incapacity or prolongation of hospi-
talisation) should be reported immediately on a Serious
A d v e r s eE v e n t sF o r mo nl i n eo rb yF A X .S e r i o u s
Adverse Events attributed to the trial treatment or
participation in the trial will be reported to the Data
Monitoring Committee (DMC), Trial sponsors and
ethics committees.
Follow up
Detection of DVT
Patients should have a CDU of the veins in both legs
between Day 7 and Day 10 and usually between Day 25
and 30. We define minimum acceptable technical stan-
dards for ultrasound equipment and stipulate that the
trial ultrasonographers should have performed CDU to
diagnose DVTs as part of a clinical service. We asked
them to visualise the popliteal and femoral veins in both
legs but do not insist that they routinely visualise the six
deep veins in the calf since detecting thrombosis in
these is far less reliable. We obtain a hard copy of posi-
tive scans to enable our trial radiologist (JR), who is
blinded to group allocation, to verify each primary out-
come. We do not perform central verification of nega-
tive scans because, with ultrasound techniques,
meaningful verification of static images is difficult. If the
second ultrasound is delayed to more than 30 days and
shows a popliteal or femoral DVT, it is included in the
primary outcome. However, we do not include a proxi-
mal DVT in our primary outcome which only comes to
attention because of symptoms starting more than 30
days after enrollment because this might introduce bias.
Where the randomising person judges that it is likely
to be impractical to perform a CDU between Days 25
and 30, they may, prior to randomisation, stipulate that
a CDU will only be performed between Days 7 and 10.
This might be the case if the patient is likely to be dis-
charged home to another region or transferred to a
rehabilitation facility that does not have use of CDU
facilities and is remote from the randomising centre.
If a definite above knee DVT is detected on the first
screening CDU i.e. the patient has our primary outcome
then the second screening CDU is no longer required.
IPC should be removed completely before the patient
leaves the ward to have the CDU to ensure optimal
blinding of the primary outcome measure. The CDU
operator is asked to guess which treatment group the
patient is in prior to the examination to estimate the
effectiveness of blinding. In those patients allocated IPC
it should immediately be re-applied on return to the
ward after the screening CDU.
In hospital follow up
The local coordinator completes a discharge form for all
randomised patients on discharge from the randomising
centre or in the event of earlier death. We can not blind
the local coordinator to group allocation. If a patient is
transferred to a rehabilitation unit on a different site to
the randomising centre, and it is impractical to continue
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patient is in that unit a discharge form is completed on
transfer to that unit.
The data collected at hospital discharge includes:
￿ Use of heparin, warfarin, and antiplatelet drugs
during admission to monitor the components of
routine care and to ensure equal use in the two
treatment arms. However, an imbalance of heparin
(or similar) and warfarin may occur if IPC is effec-
t i v es i n c em o r ep a t i e n t si nt h ec o n t r o la r mw i l l
receive these drugs to treat the excess of venous
thromboembolism. The indication for their use is
therefore recorded.
￿ Use of full length or below knee graduated com-
pression stockings to monitor the components of
routine care and to ensure equal use in the two
treatment arms.
￿ Timing of initiation of IPC and adherence to treat-
ment allocation and use of IPC.
￿ Any clinical DVT or PE requiring treatment.
￿ Any complications of treatments in particular skin
problems with legs, falls resulting in injuries occur-
ring within the first 30 days after randomisation.
The discharge form includes checkboxes to record
these secondary outcomes and adverse events. The date
of occurrence of any secondary outcome is recorded
along with a free text description of the problem. The
chief investigator (MD) reviews these data centrally and
codes the events as far as possible blind to the group
allocation.
Later outcomes
The coordinating centre telephones and sends a postal
questionnaire to the General Practitioners of all patients
who survive to discharge from hospital about 24 weeks
after randomisation. This establishes that the patient is
alive prior to sending out a follow-up form and ascer-
tain whether they have had any DVT or PE since dis-
charge from the randomising centre.
Six month follow up
The Co-ordinating Centre sends a postal questionnaire
(and one postal reminder and then a telephone follow
up for non responders) to those surviving patients who
have been discharged. The six month questionnaire
aims to establish:
￿ the place of residence (own home, with relatives,
residential care or nursing home) [as a guide to
resource use]
￿ their functional status
￿ their current antithrombotic medication regimen
￿ presence of leg swelling, ulcers which might reflect
post DVT syndrome
If the patient is still in hospital when the six month
follow-up is due, the randomising clinician/nurse will be
sent a six month “in hospital” follow-up form which
should be completed with the patient. We check data
centrally for completeness and consistency and sent
monthly reports to each centre with data queries.
Management of DVT in the trial
If the clinician is satisfied that the patients has a proximal
DVT (with or without a confirmatory venogram) the
patient should be anticoagulated using subcutaneous
heparin/LMWH according to local protocols as long as
there is no contraindication. If only calf vein thrombus is
detected (by screening CDU and/or venography), the
responsible clinician may anticoagulate the patient accord-
ing to local protocols or alternatively arrange a follow up
CDU approximately seven days later to identify any propa-
gation into the popliteal vein. If definite popliteal or
femoral vein thrombus is detected the patient should be
anticoagulated unless contraindicated. If a patient develops
symptoms or signs suggestive of DVT during their admis-
sion they should be investigated by either CDU and/or
venography or MRI direct thrombus imaging and treated
according to local protocols if the diagnosis is confirmed.
Use of heparin, LMWH and Warfarin to treat DVT and/
or PE during admission is recorded on the discharge form.
Continued use of IPC in such patients is at the discretion
of the responsible clinician.
Sample size
We originally planned to enrol at least 2000 patients.
This aimed to give the Trial > 90% power (alpha 0.05)
to identify an absolute reduction of risk of our primary
outcome of 4% (about 10% to 6%). The frequency of our
primary outcome was estimated from the CLOTS trials
1 and 2. We aimed to enrol at least 75% of patients on
Days 0-2 after stroke onset. If the proportion enrolled
after Day 2 exceeds 25% of the total then the Trial
Steering Committee (TSC) canc o n s i d e rr a i s i n gt h e
overall target. This should help ensure that we do not
miss a real treatment effect because of delays in
recruitment.
In October 2010, the frequency of the primary out-
come in both groups combined was 12.2%, rather than
the anticipated 8%. The TSC therefore revised the sam-
ple size to 2800 to ensure that the trial maintained
p o w e rt od e t e c ta4 %a b s o l u t ed i f f e r e n c ei np r o x i m a l
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group to 10% in the best medical care plus IPC group).
Analyses
The trial statistician (CG) prepares analyses of the accu-
mulating data which the independent Data Monitoring
Committee (DMC) reviews in strict confidence at least
once per year. No other members of the trial team, TSC
or participants have access to these analyses.
A detailed analysis plan will be prepared by the mem-
bers of the TSC prior to the completion of enrollment
without input from the trial statistician or reference to
the unblinded data and then published on the trial web-
site. For the purposes of all primary analyses, we will
retain participants in the treatment group to which they
were originally assigned irrespective of the treatment
they actually received. We will strive to obtain full fol-
low-up data on every patient to allow a full intention-
to-treat analysis. Inevitably, some patients will be lost to
follow up. We will exclude these patients from the ana-
l y s e st h a tt h e yh a v en od a t af o r ,a n dd os e n s i t i v i t ya n a -
lyses to see the effect of these exclusions on our
conclusions. For binary outcomes (e.g. occurrence of a
primary or secondary outcome OR not), outcomes will
be presented as odds ratios and 95% confidence inter-
vals, adjusted using logistic regression for the factors
used in the minimisation algorithm. We will calculate
absolute reductions in risk from these values. The
Oxford handicap scale will be analysed in two ways -
dichotomized in OHS 0-2 vs 3-6 (by logistic regression)
and as an ordinal scale (by ordinal regression). The uti-
lity based on the EuroQol will be compared by t-tests if
the data are Normally distributed, and using an appro-
priate nonparametric test otherwise.
Preplanned subgroup analyses
Preplanned subgroup analyses include: the effect of
treatment allocation on the primary outcome subdivided
by key baseline variables:
￿ Time from stroke onset to randomisation (Day 0
o r1v s .2t o7a n dD a y0t o2v s .3 - 7 ) .S i n c eD V T
may develop very soon after stroke onset and IPC
may not influence propagation of thrombus which
has already started it is plausible that IPC will be
more effective if started earlier after stroke.
￿ Paralysis of leg (complete vs. incomplete)
￿ Stroke severity (using a validated prognostic model
[15]
￿ Use of heparin, warfarin or thrombolysis at the
time of enrolment
Subgroup analyses will be performed by observing the
change in log-likelihood when the interaction between
the treatment and the subgroup is added into a logistic
regression model. These analyses will be repeated but
using the occurrence of our primary outcome within 14
days of randomisation (instead of 30 days).
We will perform secondary on treatment analyses to
examine the extent to which non adherence to the trial
intervention might explain the estimate of effect size.
Economic analyses
Economic analysis of trial treatment effects will involve
a within trial evaluation of cost effectiveness integrated
into a decision-analytic model of longer run costs and
health effects. The within trial analysis will be conducted
on an intention-to-treat basis. The primary health end-
points will be survival times adjusted for quality of life.
A standard multiplicative model will be used to estimate
quality adjusted life years (QALYs) by the area under
linear interpolation of the EQ5D-3 L index trajectory for
each individual using survival times, the EQ5D-3 L
index score at six months and a modelled baseline
EQ5D -3 L index score. We will assess robustness using
probabilistic sensitivity analysis of the parameters used
to generate the short-run QALY estimates.
A NHS perspective will be adopted for assessing
resource use and costs. Patient-specific hospital resource
use will be measured using the duration of stay for the
index episode following randomisation. The net direct
medical cost will include the hospital stay, converted
into cost estimates using NHS per-diem hospital costs, a
cost estimate of IPC capital/equipment (and staffing
implications) and the averted costs arising from the
effects of IPC on expected DVT/PE incidence. Trial cen-
tre/region specific per-diem hospital costs will be based
on NHS reference costs in England and cost information
for NHS Scotland derived from the Scottish Health Ser-
vice Costs resource. Probabilistic sensitivity analysis will
also be used to assess the hospital cost distributions.
We will assess differences in costs and effects using
econometric methods based on a copula framework that
is particularly useful and straightforward when model-
ling joint parametric distributions. We will also sum-
marise our cost effectiveness results within a net benefit
approach using incremental net (monetary) benefit and
cost-effectiveness acceptability curves.
Costs and benefits of an effective approach to prevent-
ing DVT following stroke will accrue over time. An
important element of the economic analysis will be a
focus on longer run outcomes using a decision-analytic
model that builds on the within trial findings. The key
parameters for the patient level simulation model will
include expected survival, quality of life, long term com-
plications, such as post-thrombotic syndrome, and use
of health services over a 6 month to 5 year time hori-
zon. The model will be calibrated using distributions
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related quality of life following stroke and the long term
prognosis and cost burden of DVT in the community.
Monte Carlo probabilistic sensitivity analysis will be
used to account for uncertainty in the cost effectiveness
results based on the simulation model.
Research governance
The Principal Investigator’s (PI) in each centre is respon-
sible for:
￿ Discussing the trial with medical and nursing staff
who see stroke patients and ensure that they remain
aware of the state of the current knowledge, the
most recent trial protocol and its procedures.
￿ Delegating roles to those with appropriate knowl-
edge and skills.
￿ Ensuring that patients admitted with stroke are
considered promptly for the trial.
￿ Ensuring that the randomisation forms, radiology
report forms and discharge forms are completed and
either entered on line or sent to the coordinating
centre promptly and that copies are kept in a site
file and patient notes.
￿ Ensuring the trial is conducted in accordance with
GCP and fulfils all national and local regulatory
requirements.
￿ Ensuring that the patients’ confidentiality is not
breached.
￿ Allowing access to source data for audit and
verification.
The Co-ordinating Centre is responsible for:
￿ Providing study materials, a 24-hour randomisation
service and Helpline.
￿ Giving collaborators regular information about the
progress of the study.
￿ Helping ensure complete data collection at
discharge.
￿ Responding to any questions (e.g. from collabora-
tors) about the trial.
￿ Assuring data security and quality in accordance
with GCP and local guidelines.
￿ Ensuring trial is conducted in accordance with
GCP.
Monitoring
IPC devices carry a CE mark and are licensed for use as
a prophylaxis for venous thromboembolism. In surgical
practice, their use appears to be associated with a low
risk of adverse effects. The trial procedures are relatively
simple and place only a small burden on the patients.
No significant financial inducements are being offered
to collaborating centres to encourage their active partici-
pation or to reward high recruitment rates. Central fol-
low up of all patients at about six months after
enrolment provides confirmation of the trial participants
identity (hence avoids the need for detailed on site
source data verification of patient identity, a very
resource intensive activity). After an appropriate risk
assessment process, the trial management group and the
trial sponsors judged that: the risks of patients being
harmed by the trial interventions were small; any hazard
associated with participation in the trial was very small;
and, the risk of research misconduct are also small. The
intensity of on-site monitoring which we undertake is
based on this risk assessment. The coordinating centre
monitors the completeness, internal consistency and
validity of the data from all trial sites, and applies the
central statistical techniques proposed by Buyse et al.
[22]. From the data collected we monitor adherence to
the trial protocol. Our study monitor carries out source
data verification in a small random sample of patients
during on site visits. If concerns arise as a result of the
routine central statistical monitoring, a more detailed
investigation including on-site verification of data is car-
ried out.
The trial is jointly sponsored by NHS Lothian and the
University of Edinburgh.
Discussion
This is to our knowledge, the largest RCT of IPC ever.
It will include more patients and outcome events (proxi-
mal DVTs) than all previous RCTs of IPC combined.
The patients are enrolled by over 80 hospitals which
hopefully will mean that our results will have good
external validity. Central randomisation, mainly blinded
assessment of our primary outcome, low losses to follow
up and intention to treat analysis will minimise bias.
In this trial the primary outcome is an intermediate
level outcome. Ideally, we would demonstrate the effect
of IPC on symptomatic DVT, PE, survival and func-
tional status. However, symptomatic events are far rarer
than those identified by screening CDU and the impact
on survival and functional status relatively small. There-
fore, a trial would need to enrol many tens of thousands
of patients to demonstrate moderate-sized, but clinically
important, effects on these outcomes. We can justify the
use of an intermediate outcome because of the clinical
significance attributed to even asymptomatic DVT in
popliteal or femoral veins which most clinicians treat
with anticoagulant therapy. Also, IPC is very unlikely to
have adverse effects beyond those which will be directly
measured in the trial i.e. damage to skin on legs, or
falls. IPC should not restrict mobilisation because it can
be worn during bed to chair transfers and will be taken
off when the patient is able to mobilise independently.
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acute phase, which could in turn influence stroke out-
come, by increasing venous return - however empirical
studies have not demonstrated a significant effect of IPC
on blood pressure. The CLOTS trial may underestimate
the clinical importance of the effects of IPC because we
do not systematically screen for pulmonary emboli with
routine imaging. Also, because we systematically screen
for asymptomatic DVT, many patients receive treatment
with anticoagulants to lessen the risk of symptomatic
events occurring.
In stroke patients, and those with other acute medical
conditions, IPC can only be applied after the patient has
become immobile. Immobility may then persist for
weeks or even be permanent in such patients. DVTs
may develop rapidly and cannot then be so effectively
prevented by a treatment starting sometime after the
initial period of paralysis and immobility. Clearly, we
cannot test the effectiveness of IPC applied before
stroke onset but it is a challenge to recruit patients into
a RCT, with the need to collect informed consent, as
early after the stroke as IPC might be applied if it was
being used in routine clinical practice. For this reason
we are trying to maximise the proportion of patients
recruited on Day 0 or 1.
Another challenge in this trial is to optimise adher-
ence to the IPC. To be a fair test of the device we need
to achieve levels of adherence close to those which
w o u l db ea c h i e v e di fw ek n e wt h a ti tw a se f f e c t i v e .
However, in a randomised trial one has to achieve a bal-
ance between cajoling patients to persist with treatment
which they might find uncomfortable whilst allowing
them to stop the treatment without having to give a rea-
son as stated in the consent procedure. Inevitably,
adherence wanes over time because some patients find
the IPC uncomfortable or staff became concerned by
the condition of patient’ss k i n .I ti sf o rt h i sr e a s o nt h a t
w ea r ep l a n n i n gt op e r f o r mas e c o n d a r ya n a l y s i so f
proximal DVTs up to 14 days.
Symptomatic DVTs affecting the popliteal or femoral
veins, which occur within 30 days of randomisation, will
be counted in the primary endpoint. A symptomatic
DVT is defined for the purposes of this trial as a DVT
confirmed on investigation with associated clinical fea-
tures including leg swelling, pain, obvious erythema or a
proven pulmonary embolus. Sometimes these features
may not be recognised prior to a positive screening
CDU but if present the DVT should be reported as
symptomatic. We will distinguish those DVTs which
were identified primarily on a screening CDU from
those which were diagnosed clinically and confirmed on
subsequent investigation since the detection of the latter
symptomatic DVTs is not blinded and hence prone to
ascertainment bias. A secondary analysis excluding these
symptomatic DVTs identified before any CDU will also
be performed. Inevitably, some patients will not survive
to have routine CDUs and many of these will not have a
detailed autopsy to establish whether they had a DVT or
PE prior to death. However, it is possible that there will
be an imbalance in the number of such deaths between
the treatment groups especially if IPC is very effective in
reducing the risk of fatal PE. Therefore, we will firstly
present the numbers Alive with no DVT, Alive with
DVT, Dead without prior DVT, and Missing. We will
carry out our analyses in two ways: comparing DVT
with no DVT with dead and missing patients excluded;
and comparing DVT + dead with no DVT + missing.
We have tried to maximise the benefits to patients
from participation in the trial. Our patient information
leaflet provides important general information about
stroke and its treatment. Our follow up with screening
CDU allows us to detect asymptomatic DVTs which
may, if undetected and untreated, lead to fatal pulmon-
ary embolism. Lastly we feedback the information
gleaned for the 6 month follow-up regarding patients’
functional status, mood and pain back to the patients’
general practitioners so that this information can inform
their future management.
Limitations of the CLOTS trial 3 include the imperfect
blinding of the ultrasonographers which could bias
detection of our primary outcome, and our inability to
blind patients and caregiversw h i c hm i g h tb i a sa s s e s s -
ment of some of the secondary outcomes. Other limita-
tions included: lack of screening logs; lack of central
verification of negative scans or 100% source data verifi-
cation, but we consider these are unlikely to introduce
bias or alter the external validity of the results.
Trial status
The first patient was enrolled into CLOTS 3 on the 8
th
Dec 2008. We expect to complete recruitment of 2800
patients by the end of September 2012 and to report the
results in the first half of 2013.
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